Azalides and methods of making same
AssigneePfizer Inc.
InventorsThomas N. O'Connell, Brook K. Morse, Hamish Alastair Irvine McArthur, John Philip Dirlam
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of preparing compounds of Formula 1: and to pharmaceutically acceptable salts and solvates thereof, and to methods for preparing same. The compounds of Formula 1 are antibacterial agents that may be used to treat various bacterial and protozoal infections, and may also be used to treat cancer. The invention also relates to pharmaceutical compositions comprising the compounds of Formula 1, and to methods of treating sbacterial and protozoal infections by administering compounds of Formula 1.s
Claims33
A compound of Formula 1:
- or a pharmaceutically acceptable salt or solvates thereof, wherein:
- X is —N(Ra)CH2—, wherein the first dash of each of the foregoing X groups is attached to the C-10 carbon of the compound of Formula 1 and the last dash of each group is attached to the C-8 carbon of the compound of Formula 1, and Ra is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, —(CH2)m(C6-C10 aryl), and —(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4;
- R1 is straight-chain or alpha-branched C1-C8 alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may be substituted by one or more hydroxyl groups;
- a C3-C8 cycloalkyl or C5-C8 cycloalkenyl group, either of which may be substituted by methyl or one or more hydroxyl or one or more C1-C4 alkyl groups or halo atoms;
- or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated, and which may be substituted by one or more C1-C4 alkyl groups or halo atoms or a group of the formula SRb, wherein Rb is C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl or substituted phenyl wherein the substituent is C1-C4 alkyl, C1-C4 alkoxy or halo or a 3 to 6 membered oxygen or sulfur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may be substituted by one or more C1-C4 alkyl groups or halo atoms;
- or R1 is phenyl which may be substituted with at least one substituent selected from C1-C4 alkyl, C1-C4 alkoxy and C1-C4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano;
- or R1 is of the formula
- wherein Z1 is O, S or —CH2—, and a, b, c, and d is each independently an integer ranging from0 to 2 and a+b+c+d#5;
- R2 is H or OH;
- R3 is H or —C(O)NRcRd, wherein each of Rc and Rd is independently H, C1-C10 alkyl, C2-C20 alkenyl, C2-C10 alkynyl, —(CH2)m(C6-C10 aryl), or —(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein each of the foregoing Rc and Rd groups, except H, may be substituted by 1 to 3 Q groups;
- or wherein Rc and Rd may be taken together to form a 4-7 membered saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings may include 1 or 2 heteroatoms selected from O, S and N, in addition to the nitrogen to which Rc and Rd are attached, and said saturated ring may include 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings may be substituted by 1 to 3 Q groups;
- or R2 and R3 taken together form a carbonate ring;
- R4 is H, OH, O(C1-C10 alkyl);
- R5 is H, —C(O)Re, —C(O)ORe, —C(O)NReRf, or a hydroxy protecting group, and Re and Rf is each independently H or C1-C6 alkyl;
- R6 is H or OH;
- R7 is H or OH;
- R8 is C1-C10 alkyl, C2-C20 alkenyl, C2-C10 alkynyl, cyano, —CH2S(O)nRg wherein n is an integer ranging from 0 to 2, —CH2ORg, —CH2N(ORh)Rg, —CH2NRgRi, —(CH2)m(C6-C12 aryl), or —(CH2)m(5-10 membered heteroalkyl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R8 groups may be substituted by 1 to 3 Q groups;
- each Rg is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, —(CH2)qCRg(1)Rg(2)(CH2)rNRg(3)Rg(4) wherein q and r is each independently an integer ranging from 0 to 3 except q and r are not both 0, —(CH2)m(C6-C10 aryl), or —(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing Rg groups, except H, may be substituted by 1 to 3 Q groups;
- each of Rg(1), Rg(2), R3(3) and Rg(4) is independently selected from H, C1-C10 alkyl, —(CH2)m(C6-C10 aryl), or —(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing Rg(1), Rg(2), Rg(3) and Rg(4) groups, except H, may be substituted by 1 to 3 Q groups;
- or Rg(1) and Rg(3) are taken together to form —(CH2)p— wherein p is an integer ranging from 0 to 3 such that a 4-7 membered saturated ring is formed that may include 1 or 2 carbon-carbon double or triple bonds;
- or Rg(3) and Rg(4) are taken together to form a 4-10 membered monocyclic or polycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings may include 1 or 2 heteroatoms selected from O, S and N, in addition to the nitrogen to which Rg(3) and Rg(4) are attached, said saturated ring may include 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings may be substituted by 1 to 3 Q groups;
- Rh is H or C1-C6 alkyl;
- Ri is H, C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, wherein the foregoing Ri group may be substituted by 1 to 3 substituents independently selected from halo, OH, and O(C1-C6 alkyl);
- and if R8 is —CH2NRgRi, then Rg and Ri may be taken together to form a 4-10 membered saturated monocyclic or polycycic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings may include 1 or 2 heteroatoms selected from O, S and N, in addition to the nitrogen to which Rg and Ri are attached, said saturated ring may include 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings may be substituted by 1 to 3 Q groups;
- or R7 and R8 are taken together to form an oxazolyl ring as shown below
- wherein Z2 is —SRg, —(CH2)nC(O)Rg wherein n is 0 or 1, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, —(CH2)m(C6-C10 aryl), or —(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing Z2 groups may be substituted by 1 to 3 Q groups;
- each Q is independently selected from halo, cyano, nitro, trifluoromethyl, azido, —C(O)Q1, —OC(O)Q1, —C(O)OQ1, —OC(O)OQ1, —NQ2C(O)Q3, —C(O)NQ2Q3, —NQ2Q3, hydoxy, C1-C6 alkyl, C1-C6 alkoxy, —(CH2)m(C6-C10 aryl), and —(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein said aryl and heteroaryl substituents may be substituted by 1 or 2 subsfituents independently selected from halo, cyano, nitro, trifluoromethyl, azide, —C(O)Q1, —C(O)OQ1, —OC(O)OQ1, —NQ2C(O)Q3, —C(O)NQ2Q3, —NQ2Q3, hydroxy, C1-C6 alkyl, and C1-C6 alkoxy;
- each Q1, Q2 and Q3 is independently selected from H, OH, C1-C10 alkyl, C1-C6 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, —(CH2)m(C6-C10 aryl), and —(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4;
- R9 is H or CH3;
- and
- R10 is H or CH3.
A method of preparing an azalide compound having at least one sugar comprising contacting an azalide aglycone compound with a biological culture under conditions suitable for the formation of an azalide having at least one sugar, and isolating from the biological culture an azalide having at least one sugar.
Dependencies are inferred from the claim text.